Sbe β cd

All C57BL/6J mice were purchased from SPF biotechnology (Beijing, China). The mice were placed in specific pathogen-free (SPF) barrier facilities and maintained in ventilated cages, with free access to food and water.
Young C57BL/6J mice (male, 6 weeks) were randomly divided into three groups, each group contained 12–15 mice. To induce lung fibrosis, mice from two groups received 2 mg/kg bleomycin (MCE, HY-17565) through intratracheal instillation, and one group received PBS as a sham. After one week, the two bleomycin-treated groups received 0.5 mg/kg ML216 dissolved in a solvent containing saline with 10% DMSO, 20% SBE-β-CD (Sigma, H107) or a solvent control through intraperitoneal injections (i.p.), respectively. The injections were conducted twice a week for 3 weeks, while the sham group received the solvent control at the same frequency. Mouse body weight was measured twice a week.
Aged C57BL/6J mice (female, 22 months) were randomly divided into two groups, each group contained 10–11 mice. The two groups received 1 mg/kg ML216 dissolved in a solvent containing saline with 10% DMSO, 20% SBE-β-CD (Sigma, H107) or a solvent control through intraperitoneal injections (i.p.), respectively. The injections were conducted twice a week for 5 weeks. Mouse body weight was measured twice a week.

A sample of etoricoxib was provided by Bright life Pharmaceuticals, Egypt, β-CD (water ≤14%), HP β-CD (DS of 4.9), SBE β-CD (water at least 4%, average DS of 6.5) (Sigma Aldrich—Burlington, MA, USA), F-melt^® Type C (a gift sample from FUJI Chemical Industry Co., Ltd., Tokyo, Japan) Prosolv^® ODT G2 (a gift sample from JRS Pharma, Rosenberg, Germany), and Ethanol 99.9% (Lab Chem, Cairo, Egypt). All the reagents used were of pharmaceutical grade.

Antibodies against β-Actin (AC026, 1:10000), NUDT1 (A13330, 1:1000 for immunoblots, 1:200 for immunoprecipitation), NOX4 (A11274, 1:1000), H3 (A2348, 1:1000), NCL (A5904, 1:1000) were obtained from ABclonal. PLK1 (4513 S, 1:1000), Phospho-PLK1 (Thr210) (5472 T, 1:1000), MYC (13987, 1:1000 for immunoblots), cleaved-Caspase 3 (Asp175) (9661 S, 1:1000 for immunoblots, 1:100 for IHC) were obtained from Cell Signaling technology. Flag-tag (F1804, 1 μg for immunoprecipitation) was obtained from Sigma–Aldrich. N-MYC (sc-53993, 1:1000 for immunoblots, 4 μg for ChIP) and PCNA (sc-56, 1:2000 for IHC) were obtained from Santa Cruz Biotechnology. 8-oxo-dG (AB5830, 1:300 for IHC) and γH2AX (05-636, 1:200 for IHC, 1:100 for IF, 1:1000 for immunoblots) were obtained from Millipore. HRP-conjugated goat anti-mouse (115-035-003, 1:5000) and anti-rabbit (111-035-003, 1:5000) secondary antibodies were obtained from Jackson ImmunoResearch Laboratories. The Phospho-NUDT1 S121 antibody was generated by Dia-An Technology by immunizing rabbits with phosphorylated S121 peptides (PDD-(phospho)S-YWF) conjugated with carrier protein keyhole limpet hemacyanin.
Other chemicals include 4-OH Tamoxifen, Tetracycline HCl, and TH287 (Selleck Chemicals); Acetylcysteine, BI6727, MG132, Pomalidomide and SBE-β-CD (MCE); CHX (Sigma–Aldrich); DAPI (Yeasen); Alexa488-conjugated avidin (Invitrogen).